<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02123667</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-01535AC1-01</org_study_id>
    <secondary_id>CCD-01535AC1-01</secondary_id>
    <nct_id>NCT02123667</nct_id>
  </id_info>
  <brief_title>AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)</brief_title>
  <acronym>ATLANTIS</acronym>
  <official_title>AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS); Multinational, Multicentre, Non-pharmacological Intervention, Cross-sectional and Longitudinal Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multinational, multicentre, non-pharmacological intervention, cross-sectional and&#xD;
      longitudinal study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Large non pharmacological studies on Small Airways Disease&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2014</start_date>
  <completion_date type="Actual">March 4, 2017</completion_date>
  <primary_completion_date type="Actual">March 4, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the role of small airways abnormalities in the clinical manifestations of asthma.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">872</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Asthmatic patients</arm_group_label>
    <description>asthmatic patients 18 to 65</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>Volunteers 18 to 65</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Optional bronchoscopy with endobronchial and trans-bronchial biopsy will be applicable in&#xD;
      selected sites only in EU and US. Total number of inflammatory cells and quantification of&#xD;
      specific cells including eosinophils, T cells and macrophages will be performed. Gene&#xD;
      expression profiles (including RNA) will be performed at a later date for future analysis on&#xD;
      the pathobiology of asthma which will be defined in future specific protocols&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        900 subjects divided into 800 asthmatic patients and 100 healthy controls will be included.&#xD;
        Recruitment will be balanced, at the extent possible, in order to achieve at least &gt; 150&#xD;
        patients each for steps 1 - 4 and &gt; 50 patients for step 5 as indicated in the&#xD;
        international guidelines (GINA 2012) on the basis of their previous therapy. The 150&#xD;
        healthy controls will be recruited on the basis of absence of respiratory symptoms, airway&#xD;
        obstruction and hyper responsiveness.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Asthmatic patient inclusion criteria&#xD;
&#xD;
          1. Male or female patients aged ≥ 18 and ≤ 65 years, who have signed an Informed Consent&#xD;
             form&#xD;
&#xD;
          2. Clinical diagnosis of asthma f&#xD;
&#xD;
               1. Positive response to methacholine challenge test&#xD;
&#xD;
               2. Positive response to a reversibility test or&#xD;
&#xD;
               3. Peak Flow variability (i.e. highest - lowest PEF over the day/mean value of the&#xD;
                  two, × 100) &gt; 20% or&#xD;
&#xD;
               4. Documented response (defined as ΔFEV1 ≥ 12% and ≥ 200 mL) after a cycle (e.g., 4&#xD;
                  weeks) of regular maintenance anti-asthma treatment.&#xD;
&#xD;
          3. Patients with stable asthma.&#xD;
&#xD;
          4. Current smoker, ex-smoker or lifelong non-smoker Healthy subject inclusion criteria&#xD;
&#xD;
        1. Male or female patients aged ≥ 18 and ≤ 65 years 2. No clinical history of asthma or&#xD;
        COPD 3. Current smoker, ex-smoker or lifelong non-smokers 4. Normal spirometry 5. Normal&#xD;
        airways responsiveness Asthmatic patient exclusion criteria&#xD;
&#xD;
          1. Cigarette smoking &gt; 10 packyears&#xD;
&#xD;
          2. diagnosis of COPD&#xD;
&#xD;
          3. Asthma exacerbation in the 8 weeks prior to baseline visit&#xD;
&#xD;
          4. Clinical or functional uncontrolled respiratory, haematological, immunologic, renal,&#xD;
             neurologic, hepatic, endocrinal or other disease, or any condition that might&#xD;
             compromise the results or interpretation of the study.&#xD;
&#xD;
          5. Pregnant or lactating women&#xD;
&#xD;
          6. Participation in an interventional clinical trial &lt;12 weeks preceding baseline visit&#xD;
&#xD;
          7. Inability to comply with study procedures.&#xD;
&#xD;
          8. Alcohol or drug abuse. Healthy subject exclusion criteria&#xD;
&#xD;
        1. Cigarette smoking history &gt; 10 packyears 2. Diagnosed upper and/or lower respiratory&#xD;
        disease(s). 3. Clinical or functional uncontrolled haematological, immunologic, renal,&#xD;
        neurologic, hepatic, endocrinal or other disease, or any condition that mightp compromise&#xD;
        the results or interpretation of the study.&#xD;
&#xD;
        4. Pregnant or lactating women 5. Participation in an interventional clinical trial &lt;12&#xD;
        weeks preceding baseline visit 6. Inability to comply with study procedures. 7. Alcohol or&#xD;
        drug abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Kraft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirkje S Postma, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0503</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0502</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0504</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0501</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Emilio Pizzichini</name>
      <address>
        <city>Florianópolis</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Alberto Cukier</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. Rafael Stelmach</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0201</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gao</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yuanlin Song</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032,</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qingling Zhang</name>
      <address>
        <city>Hangzhou</city>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0303</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>D-22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0301</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0302</name>
      <address>
        <city>Leipzig</city>
        <zip>D-04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0104</name>
      <address>
        <city>Ferrara</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0101</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scichilone</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chetta</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0103</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0102</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>W. Boersma</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. J. Vroegop</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. M. vd Berge</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. M. Broeders</name>
      <address>
        <city>Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0402</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site #0401</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Postma DS, Brightling C, Baldi S, Van den Berge M, Fabbri LM, Gagnatelli A, Papi A, Van der Molen T, Rabe KF, Siddiqui S, Singh D, Nicolini G, Kraft M; ATLANTIS study group. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. Lancet Respir Med. 2019 May;7(5):402-416. doi: 10.1016/S2213-2600(19)30049-9. Epub 2019 Mar 12. Erratum in: Lancet Respir Med. 2019 Sep;7(9):e28.</citation>
    <PMID>30876830</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2014</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

